

Amunix Pharmaceuticals Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has raised $117 million in Series B financing. Viking Global Investors led the round.
Source: Press Release
Amunix Pharmaceuticals Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has raised $117 million in Series B financing.
Amunix Pharmaceuticals Inc, a biopharmaceutical company focused on treating patients with solid tumor cancers, has raised $117 million in Series B financing. Viking Global Investors led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination